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Abstract
Background: The anti-human Fas/APO-1/CD95 (Fas) mouse/human chimeric monoclonal IgM antibody ARG098
(ARG098) targets the human Fas molecule. The cytotoxic effects of ARG098 on cells isolated from RA patients, on
normal cells in vitro, and on RA synovial tissue and cartilage in vivo using implanted rheumatoid tissues in an SCID
mouse model (SCID-HuRAg) were investigated to examine the potential of ARG098 as a therapy for RA.
Methods: ARG098 binding to each cell was analyzed by cytometry. The effects of ARG098 on several cells were
assessed by a cell viability assay in vitro. Effects on the RA synovium, lymphocytes, and cartilage were assessed
in vivo using the SCID-HuRAg mouse model.
Results: ARG098 bound to cell surface Fas molecules, and induced apoptosis in Fas-expressing RA synoviocytes
and infiltrating lymphocytes in the RA synovium in a dose-dependent manner. However, ARG098 did not affect the
cell viability of peripheral blood mononuclear cells of RA patients or normal chondrocytes. ARG098 also induced
apoptosis in RA synoviocytes and infiltrating lymphocytes in the RA synovium in vivo. The destruction of cartilage
due to synovial invasion was inhibited by ARG098 injection in the modified SCID-HuRAg mouse model.
Conclusions: ARG098 treatment suppressed RA synovial hyperplasia through the induction of apoptosis and
prevented cartilage destruction in vivo. These results suggest that ARG098 might become a new therapy for RA.
Background
Rheumatoid arthritis (RA) is a chronic, inflammatory,
and proliferative autoimmune disease characterized by
synovial pannus formation that causes joint pain and
swelling [1]. Inflammation and proliferation of synovio-
cytes erodes the cartilage and leads to joint bone
destruction. One of the most important pathogenetic
factors in RA that worsens the disease is synovial hyper-
trophy. Consequently, an effective strategy for RA treat-
ment is the removal of synovial hyperplasia to prevent
cartilage destruction and increase the quality of life
(QOL) of patients [1,2].
Apoptosis is an essential biological system for develop-
ment, differentiation, and homeostasis [3]. Apoptotic cell
death exists in the RA synovium [4] but cell prolifera-
tion dominates in RA-affected joints, indicating that the
balance between cell growth and death in the synovium
collapses in RA joints [5] or that some Fas-resistant sig-
nals are activated in the RA synovium [6,7].
Most of the mechanisms affecting the abnormal over-
growth in the RA synovium remain unclear but a large
section of the RA synovium is sensitive to apoptosis sig-
nals, and the anti-Fas/APO-1/CD95 (Fas) antibody
induces apoptosis in the RA synovium [4] and decreases
joint swelling [8]. On this basis, we hypothesized that
this anti-Fas antibody would restore balance and reduce
hyperplasia in RA joints. Inducing apoptosis in the RA
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[5,9,10].
On the other hand, because the anti-Fas antibody is a
potent inducer of apoptosis, it is possible that the induc-
tion of apoptosis in non-target cells or organs could lead
to severe adverse effects. For example, functional APO-
1/Fas molecules are expressed on the surface of human
hepatocytes [11] and induction of apoptosis in murine
hepatocytes by the anti-Fas antibody has been shown to
be lethal [12].
In this study, we evaluated the efficacy of a novel anti-
human Fas mouse/human chimeric monoclonal anti-
body, ARG098, and its toxicity towards non-target cells
or organs. In addition, the potency of ARG098 has been
assessed in vivo using severe combined immunodeficient
(SCID) mice implanted with the RA synovium (SCID-
HuRAg) [13]. This murine model mimics human RA-
affected joints [14-17].
Methods
Reagents
ARG098 was constructed by ligating the variable region
of an anti-human Fas/APO-1/CD95 mouse monoclonal
antibody, anti-APO-1 [18], with the constant region of
the human antibody. The plasmid was transfected into
the ARG098 mouse myeloma cell line, and the ARG098
antibody was secreted in the culture medium and
purified.
The sources of the other materials used in this study are
as follows: human IgM was obtained from ICN Biomedi-
cals Inc. (Aliso Viejo, CA, USA), chondrocyte basal med-
ium supplemented with chondrocyte growth supplement
was obtained from Cell Applications, Inc. (San Diego, CA,
USA), and the neutralizing antibody anti-human APO-1/
Fas (SM1/23) was obtained from Bender Medsystems
GmbH (Vienna, Austria). Recombinant human tumor
necrosis factor-a (TNF-a) and recombinant human inter-
leukin-1b (IL-1b) were purchased from R & D Systems
(Minneapolis, MN, USA). The Cell Counting Kit-8 was
obtained from Dojindo Laboratories (Kumamoto, Japan),
and the CellTiter-Glo™ Luminescent Cell Viability Assay
and CytoTox96® Non-Radioactive Cytotoxicity Assay Kits
were purchased from Promega (Madison, WI, USA). The
Annexin V/FITC Kit was obtained from Takara Bio Inc.
(Shiga, Japan), and the PerCP-labeled anti-human CD4
antibody, PE-labeled anti-human CD8 antibody, PE-
labeled mouse IgG1, and PerCP-labeled mouse IgG1 were
purchased from BD Biosciences (Franklin Lakes, NJ,
USA). In situ apoptosis detection kit was purchased from
Takara Bio Co., Ltd. (Shiga, Japan).
Cell isolation and cell culture (cells and tissues)
The experimental procedure followed the Declaration of
Helsinki, and was approved and monitored by the Ethics
Review Board on Human Tissue Research of Santen
Pharmaceutical Co., Ltd., St. Marianna University School
of Medicine and Matsubara Mayflower Hospital. All
synoviums, cartilages and peripheral blood samples were
taken from RA patients with their informed consent. RA
synoviums and cartilage samples were supplied immedi-
ately after synovectomy for RA treatment. None of the
RA patients were treated with biological agents.
Synoviums were minced with scissors and digested in
DMEM containing 1 mg/mL collagenase at 37°C for 30
min. Isolated cells were suspended in Ham’sF - 1 2m e d -
ium supplemented with 10% FBS, 100 U/mL penicillin,
and 100 μg/mL streptomycin, and cultured at 37°C in
5% CO2. After 1 day of incubation, the cells which did
not adhere (RA synovium-infiltrating lymphocytes) were
separated from those that adhered to the culture plates
(RA synoviocytes). RA synoviocytes prepared using the
same methods were heteromorphous and belonged to
three different types: dendritic cells, macrophage cells,
and fibroblast-like cells [4], however, the majority of our
tested cell population may be synovial fibroblasts. All
experiments were performed using RA synoviocytes
within the fifth passage, and using RA synovium-
infiltrating lymphocytes without further passage.
Peripheral blood mononuclear cells (PBMCs) were iso-
lated from the peripheral blood of RA patients (the
same patients who underwent synovectomy) by density
centrifugation. All experiments with RA synoviocytes,
RA synovium-infiltrating lymphocytes, and PBMCs were
performed using 5 different samples derived from 5 RA
patients.
Human chondrocyte culture
Normal human chondrocytes were purchased from Cell
Applications, Inc., and were three-dimensionally cul-
tured in alginate beads in chondrocyte basal medium
supplemented with chondrocyte growth supplement and
preserved at 37°C in 5% CO2 to maintain cell conditions
[19]. Experiments with human chondrocytes were per-
formed using 3-5 different cell lots.
Flow cytometry
Cells were incubated with 1 μg/mL human IgM or
ARG098 for 30 min on ice. For investigating the effect
of the neutralizing antibody, cells were incubated with
10 μg/mL of the neutralizing antibody prior to incuba-
tion with human IgM or ARG098. For individual
analysis of CD4/CD8 T cells, 1 μg/mL of PerCP-labeled
anti-human CD4 antibody, PE-labeled anti-human CD8
antibody or PE-labeled mouse IgG1, and PerCP-labeled
mouse IgG1 were added to the reaction mixture with
ARG098. After washing, the cells were incubated with
FITC-labeled anti-human IgM antibody and the fluores-
cence intensity was determined using the fluorescence-
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Tokyo, Japan).
Cell viability assay
Twenty-four hours after the antibody treatments, a cell
viability assay was performed using a formazan dye
available with the Cell-Counting Kit-8. Briefly, cells were
seeded in 96-well plates and incubated with antibodies
for 24 h. The Cell-Counting Kit-8 reagents were then
added to the culture medium. After 2 h of incubation at
37°C, absorbance was measured at 450 nm. The percen-
tage of cell viability was calculated based on the 450 nm
absorbance values of non-treated cells.
In the chondrocyte cell viability analyses, one human
chondrocyte alginate bead was seeded in a well of a 96-
well plate and incubated with medium containing anti-
body. Twenty-four hours after the antibody treatment,
cell viability was assessed using the Cell Counting Kit-8.
Lymphocyte cell viability was assessed by the ATP
staining method using the CellTiter-Glo™ Luminescent
Cell Viability Assay Kit. Cells were seeded in 96-well
plates and incubated with antibodies for 24 h. The Cell-
Titer-Glo™ Luminescent Cell Viability Assay Kit reagents
were then added and the luminescence intensity was
measured after incubation for 10 min at room
temperature.
Annexin-V/PI staining
RA synoviocytes were incubated with antibodies for 6 h.
Cells were harvested, and stained with PI and FITC-con-
jugated annexin-V [20]. Fluorescence intensity (annexin-
V positive) was analyzed using the FACSCaliber 3A.
Preincubation of RA synoviocytes with cytokines
RA synoviocytes were incubated with 5 ng/mL of TNF-
a or 0.5 ng/mL of IL-1b for 5 days. The concentrations
of TNF-a and IL-1b were determined based on their
possible concentrations in synovial fluids of RA-affected
joints [21,22].
Animals
Four-week-old male CB17/Icr Crj-SCID mice were pur-
chased from Charles River Japan (Yokohama, Japan).
The mice were housed in pathogen-free facilities, and
water and food were provided ad libitum.M i c ea g e d
5-8 weeks were used for the experiments.
Preparation of the SCID-HuRAg cartilage co-implantation
mouse model
All animal experimental procedures and care were
approved and monitored by the Institutional Animal
Care and Use Committee of Santen Pharmaceutical Co.,
L t d .T h eS C I D - H u R A gm i c ew e r ep r o d u c e db yt h e
method established by Sakai et al. [13].
In addition, to study the effect of ARG098 on cartilage
destruction in this model, RA synovial tissue samples of
about 1 cm
3 and suitable pieces of RA cartilage were
grafted subcutaneously on the backs of SCID mice that
were anesthetized with ketamine and xylazine. A differ-
ence between the SCID-HuRAg mouse model used in
previous studies and that used in this study is that the
cartilages used in this study were derived from RA
patients.
ARG098 treatment in vivo
ARG098 or control human IgM antibody was directly
injected into the synovial tissues 6 weeks after tissue
implantation. To assess the induction of apoptosis by
ARG098, implanted tissues were fixed in formalin 24 h
after antibody injection. For histopathological analysis of
the tissues, mice were euthanized and the implanted tis-
sues were isolated 4 weeks after antibody injection. To
assess cell numbers in the tissues, cells were counted in
4 areas of the hematoxylin and eosin (HE)-stained
tissues.
Detection of apoptosis by DNA nick end labeling and
histopathological analysis
Apoptosis was detected by DNA nick end labeling using
the In situ apoptosis detection kit. The number of posi-
tively stained cells was counted in each tissue sample.
Serial sections were stained with HE for comparison
with the nick end labeling results.
Other tissues were fixed with formalin, embedded in
paraffin, and sectioned. The slides were stained with HE
using standard methods.
Statistical analyses
Data were analyzed using SAS software (version 8.2).
The cytotoxic effects of ARG098 were analyzed by com-
parison with the untreated cells/group using Dunnett’s
or Steel’s test when the data were homoscedastic or het-
eroscedastic, respectively. The cytotoxic effects of
ARG098 on RA synoviocytes were compared with those
of human IgM or ARG098 after pretreatment with the
Fas-neutralizing antibody SM1/23 using Student’s t-test.
The cell number in the grafted tissue and the effects of
ARG098 were analyzed by comparison with untreated
or human IgM-treated tissues using Student’s t-test
when the data were homoscedastic. P values <0.05 were
deemed to indicate statistical significance.
Results
Induction of apoptosis in RA synoviocytes
The binding of ARG098 was assessed by flow cytometry,
and the binding ability was detected in the synoviocytes
isolated from RA patients (Figure 1A). This binding was
completely displaced by neutralizing antibody treatment
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the anti-Fas antibody clone UB2 (unpublished data).
These data indicate that ARG098 recognized the Fas
molecule on the RA synoviocyte cell surface. These
experiments were performed using 5 different RA syno-
viocyte samples derived from the 5 different RA
patients, and ARG098 binding and displacement was
observed in all experiments. The RA synoviocytes
expressed Fas at a rate of 60 ± 8.9% in the 5 different
synoviocyte samples.
RA synoviocyte viability decreased after the 24-h treat-
ment with ARG098 at a concentration of 10 ng/mL or
higher (Figure 1C). The decrease in RA synoviocyte via-
bility dramatically disappeared following pretreatment
with the neutralizing antibody clone SM1/23 (Figure
1D). Moreover, ARG098 at 100 ng/mL induced
annexin-V staining within 6 h of treatment (Figure 1E).
Because annexin-V staining occurs in the early phase of
apoptosis [20], this result indicates that ARG098
induced apoptosis in the RA synoviocytes. The results of
these cell cytotoxicity experiments were similar among
the synoviocyte samples obtained from the 5 different
RA patients.
Induction of apoptosis in cytokine-treated RA
synoviocytes
To more clearly identify ARG098 potency in the target
tissues, we attempted to mimic the condition of the RA
synovium in inflammatory joints by treating the RA
synoviocytes with cytokines in vitro.
RA synoviocytes were preincubated with TNF-a or
IL-1b for 5 days and then treated with 100 ng/mL
ARG098 for 24 h. The cytotoxic effects of ARG098 were
measured and compared with those under normal
culture conditions. ARG098 induced cytotoxicity in
70%-80% of RA synoviocytes under normal conditions
and in more than 90% of RA synoviocytes when prein-
cubated with TNF-a or IL-1b (Figure 2). RA synovio-
cytes that were preincubated with cytokines were more
sensitive to ARG098 than those cultured under normal
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Figure 1 ARG098 binding and cytotoxicity to rheumatoid arthritis (RA) synoviocytes. (A) ARG098 binding activity to RA synoviocytes was
assessed by flow cytometory. The white area is stained with human IgM and the black area is stained with ARG098. (B) RA synoviocytes pretreated
with anti-Fas neutralizing antibody clone SM1/23. (C) Representative cell viability of RA synoviocytes following ARG098 treatment vs. non-treated
condition as measured by the WST assay. Black circles, ARG098; white circles, human IgM. Each point represents mean ± SEM (n = 5). **: p < 0.01 vs.
non-treated cells (Dunnett’s test). (D) Neutralization of RA synoviocyte viability by SM1/23. The cells were treated with 100 ng/mL of human IgM or
ARG098. N, non-treated group. Each bar represents mean ± SEM (n = 5). **: p < 0.01 (Student’s t-test). (E) RA synoviocytes were treated with
100 ng/mL of human IgM or ARG098. After stained with PI/annexin-V, the annexin-V positive fluorescent intensity was measured by FACSCalibur
3A. Each bar represents mean ± S.E.M of five data from synoviocytes derived from five different patients with RA.
Odani-Kawabata et al. BMC Musculoskeletal Disorders 2010, 11:221
http://www.biomedcentral.com/1471-2474/11/221
Page 4 of 11conditions. These results were similar for the synovio-
cytes obtained from all 5 RA patients.
Induction of apoptosis in synovium-infiltrating
lymphocytes but not in PBMCs
Many lymphocytes infiltrate the RA synovium and sup-
ply inflammatory cytokines [23], and these cells are also
therapeutic targets of ARG098. ARG098 induced apop-
tosis in RA synovium-infiltrating lymphocytes, which
did not adhere and were separated from the RA syno-
viums after 1 day of incubation as written in methods,
(Figure 3A) of 5 different RA patients. CD4
+CD8
- T
cells (Figure 3B) and CD4
-CD8
+ T cells (Figure 3C) in
RA synovium-infiltrating lymphocytes were mostly Fas
positive and bound by ARG098. These results indicate
that RA synovium-infiltrating lymphocytes express the
active Fas molecule and that ARG098 is effective for
removing these active inflammatory lymphocytes from
RA joints.
Simultaneously with these experiments, the effect of
ARG098 on PBMCs was tested with PBMCs isolated
from the same RA patients. ARG098 did not decrease
PBMCs viability (Figure 3D) and the results were similar
in cells isolated from the 5 different RA patients. To
compare the Fas expression in PBMCs to that of RA
synovium-infiltrating lymphocytes, we investigated
ARG098 binding in each PBMC population by flow
cytometry (Figure 3 E and F). The population size of the
CD4
+CD8
- and CD4
-CD8
+ T cells in the PBMCs was
nearly similar to that of the RA synovium-infiltrating
lymphocytes. However, ARG098 did not bind to most of
these cells, which suggests that these cells were Fas
negative. These observati o n ss u g g e s tt h a tA R G 0 9 8
induces the death of RA synovium-infiltrating lympho-
cytes but not in the PBMCs in the same RA patient at
the same time.
ARG098 binding ability and cytotoxic influence in human
chondrocytes
ARG098 is considered an anti-RA agent for intra-articu-
lar injection. With local administration, ARG098 is
directly delivered, which minimizes the adverse effects
because of low systemic exposure. If controlled well, the
toxicity of ARG098 to normal cells can be prevented
because the exposed tissues are separated by the blood
circulatory system. RA chondrocytes express Fas mole-
cules and are sensitive to apoptosis [24]. ARG098 injec-
tion could thus possibly induce apoptosis in
chondrocytes and lead to the destruction of cartilage,
which would decrease the QOL of patients.
Therefore, to evaluate the safety of ARG098, we
assessed its effects on chondrocytes. The binding of
ARG098 to human chondrocytes was detected (Figure
4A), and that was similar to that of the anti-Fas anti-
body clone UB2 (unpublished data). This binding could
be displaced by treatment with a Fas-neutralizing anti-
body (Figure 4B). Given these data, it appears that
ARG098 recognizes the Fas molecules on the cell sur-
face of human chondrocytes. However, ARG098 did not
reduce cell viability in human chondrocytes at concen-
trations of 0.1 and 1000 ng/mL or at much higher con-
centrations of 1 and 90 μg/mL (Figure 4C). Thus,
ARG098 bound to normal human chondrocytes but did
not induce cell death. ARG098 did induce cell death in
RA synoviocytes at a concentration of 10 ng/mL or
higher. However, even at 90 μg/mL, ARG098 did not
induce cell death. These results suggest that ARG098
delivered by an intra-articular injection is safe, as evi-
denced by the large difference in sensitivity between the
RA synoviocytes and chondrocytes in terms of ARG098-
induced cell death.
ARG098-induced apoptosis in RA synovium implanted in
SCID mice
The efficacy of ARG098 in vivo was evaluated using the
SCID-HuRAg mouse model. Twenty-four hours after
ARG098 injection, apoptotic cells were detected in the
infiltrating lymphocytes of the lymph follicle and syno-
viocytes in the collagen tissue in the RA synoviums
engrafted into the SCID mice. In contrast, the control
human IgM antibody did not induce apoptosis (Figure 5).
The apoptotic cell number was increased in a dose-
dependent manner by ARG098 treatment. These results
indicate that ARG098 induces apoptosis in vivo similar
to that in vitro.
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Figure 2 Cytotoxic effect of ARG098 on RA synoviocytes
preincubated with inflammatory cytokines. RA synoviocytes
(RASC) from five patients were preincubated with 5 ng/mL of tumor
necrosis factor (TNF)-a or 0.5 ng/mL of interleukine (IL)-1b for 5
days and then treated with 100 ng/mL of ARG098 for 24 h. N, non-
pretreated group. Each bar represents mean ± SEM (n = 6).
Cytotoxicity was measured with the WST assay.
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inhibits synovial growth
I nt h eR As y n o v i a lt i s s u et h a t was not implanted, infil-
trating lymphocytes were abundant and gathered to
form lymph follicles (Figure 6A). Ten weeks after
implantation, infiltrating cells remained in the RA syno-
vium. This observation is similar to what was observed
for the original synovial tissue (Figure 6B). Moreover,
synovial growth into collagen tissue, a typical character-
istic of the RA synovium, was observed, thereby resem-
bling synovial hyperplasia. When 10 μgo fh u m a nI g M
was injected into the implanted tissue (Figure 6C), many
infiltrating cells, lymph follicles, and a hypertrophied
synovium were observed, and these findings were similar
to those for the untreated tissue after implantation
( F i g u r e6 B )o rt h eo r i g i n a lt i s s u e( F i g u r e6 A ) .W h e n
10 μg of ARG098 was injected into the RA synovium
engrafted into the SCID mice, the number of infiltrating
lymphocytes markedly decreased and synovial growth
was diminished in the collagen tissue (Figure 6D). In
addition, synoviocytes were replaced by adipocytes. Cell
numbers in the ARG098-treated tissue significantly
decreased compared with those in the untreated and
human IgM-treated tissues (unpublished data).
ARG098 protects against cartilage destruction
RA synovium implanted into the SCID mice is a good
model to mimic RA-affected joints. However, to
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vs. the non-treated condition. Black circles, ARG098; white circles, human IgM. Each point represents mean ± SEM (n = 5). **: p < 0.01 vs. non-
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-CD8
+ T cells in the PBMCs from RA patients.
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Page 6 of 11estimate the efficacy and safety in the synovium and car-
tilage in the joints, modification of the model was neces-
sary. The synovium and cartilage obtained from the
same RA patient were co-implanted on the backs of the
SCID mice. When 10 μg of human IgM was injected
into the RA synovium, infiltrating lymphocytes were
abundant in the synovial tissue (Figure 7A), and the
cartilage was infiltrated and digested by the synovium
(Figure 7B). On the other hand, when 10 μgo fA R G 0 9 8
was injected into the RA synovium, the number of infil-
trating lymphocytes markedly decreased (Figure 7C).
This decrease is comparable to that observed in the
synovium-implanted model (Figure 6D). Cartilage
destruction was completely inhibited and there was little
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Page 7 of 11cartilage erosion due to synovium infiltration
(Figure 7D). The border between the synovial tissue and
cartilage could be readily detected in the ARG098-trea-
ted tissue.
Discussion
The APO-1/Fas/CD95 (Fas) molecule is a cell mem-
brane receptor [25], and the anti-Fas antibody or the
internal Fas ligand binds to Fas to induce cell apoptosis
[26]. However, IgG subtype anti-Fas antibodies may not
induce apoptosis without Fas receptor multimerization
[27]. IgG subtype anti-Fas antibodies usually need cross-
linkers or internal factors for multimer construction and
incomplete Fas multimer formation prevents apoptosis
[28,29].
Then, IgM subtype anti-Fas antibody was expected to
be suitable to activate the Fas signal effectively. There-
fore, ARG098 was constructed as a mouse-human chi-
meric antibody for the purpose of developing an anti-
RA agent for humans.
The cytotoxic activity of ARG098 toward the target
cells, i.e., RA synoviocytes and synovium-infiltrating
lymphocytes, was shown in this study. However, even
after ARG098-treatment, some ARG098-resistant RA
synoviocytes remained. The reasons for this resistance
to Fas-mediated death signals are believed to be as
follows: first, Fas-mediated apoptosis in synoviocytes is
regulated at the level of recruitment of the Fas-
associated death domain protein (FADD) to the death-
inducing signaling complex (DISC) [30]. The reason
why the RA synoviocytes preincubated with TNF-a
were more sensitive to ARG098-induced apoptosis than
the RA synoviocytes in normal culture conditions can
then be explained, at least in part, by caspase 3 and 8
up-regulation by TNF-a [31]. Second, the conditions
under which RA synoviocytes are cultured have a huge
impact on their susceptibility to the Fas signal [6]. The
cell cycling status or proliferating stage influences Fas-
mediated apoptotic signal transduction and sometimes
the RA synovium becomes resistant to Fas-mediated cell
death. Third, the PI3K/Akt-1 pathway is activated in the
cells of RA joints and this pathway activates apoptosis-
inhibitory factors [7].
We also understand that our positive in vitro results
with ARG098 may be a secondary event depending on
the tissue culture conditions such as proliferation rate,
cell cycling status and culture confluency. In our culture
condition, we have not checked what cell population are
there, but we speculate the majority of our tested cell
population may be synovial fibroblast cells which are
consisted with mixed cell status of proliferation rate and
cell cycling, etc. We suppose that there are both prolif-
erating and arresting synovial fibroblasts in our culture
with 10% FBS. Although from our in vitro results with
the experimental cell culture in 10% FBS we could not
evaluate the intrinsic quantitative efficacy of ARG098
and could not extrapolate intrinsic inv i v oresults, we
believe that some part of in vivo effects are expected by
our in vitro results.
While ARG098 is a new potentially effective tool for
the inhibition of synovial hyperplasia and joint swelling,
ARG098 could also possibly affect normal cells that
express Fas on the cell surface and this may lead to
adverse events during RA treatment. Then we checked
the effect of ARG098 on PBMCs from the same RA
patients, and on normal human chondrocytes. As
results, we could not found any adverse effect of
ARG098 on these cell viabilities, in vitro.I nc a s eo f
chondrocytes, in addition, no apoptosis or damage to
RA chondrocytes was observed in ARG098-treated tis-
sues during the histopathological assessment of
ARG098-treated RA synovium and cartilage co-
implanted in the SCID-HuRAg mice.
In addition, because functional Fas is also expressed
on the surface of human hepatocytes [11] and the anti-
Fas antibody induces apoptosis in hepatocytes [12], we
investigated whether ARG098 could induce a severe
adverse effect on normal hepatocytes. Although
ARG098 bound to normal human hepatocytes, it did
not induce cytotoxicity at concentrations less than 1000
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Figure 5 Apoptotic cell number after ARG098 treatment in RA
synovium implanted in SCID mice. Apoptotic cell numbers were
counted and are expressed as the cell number in a field. The white
bars show the apoptotic cell number in the collagen tissue. The
black bars show the apoptotic cell number in the lymph follicle.
Statistical analyses of cell number in the lymph follicle were
performed with Dunnett’s test and p values are shown in the figure.
Analysis of the collagen tissue was performed with Steel’s test. *,
p < 0.05 versus 0 μg/mouse group.
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Page 8 of 11ng/mL (unpublished data), indicating that the apoptosis-
inducible concentration of ARG098 in RA synoviocytes
or lymphocytes infiltrating the RA synovium is lower
than that in hepatocytes. This sensitivity difference can
be partly explained by inadequate preparation of the cel-
lular machinery [32] or by Fas-resistant signal activation
[7]. And also as ARG098 is intended to be delivered as
an intra-articular injection, wherein the leak speed of
ARG098 into the circulatory system is expected to be
slow and thus the hepatocyte exposure concentration
would be low. Thus, ARG098 appears to be safe in this
regard and these expectations are also supported by
other safety studies performed with ARG098 in human
tissue slices or cross-reactive animals.
TUNEL-positive cells were not abundant in the
ARG098-treated tissues in the SCID-HuRAg mice.
Apoptotic cells can be difficult to detect because the
DNA fragments detected by the TUNEL method are
readily degraded. Twenty-four hours after the injection
is considered to be the best time to detect apoptotic
cells, but not all such cells were detected in this study.
In addition, apoptotic cells are believed to be processed
and removed rapidly by phagocytes. Although TUNEL-
positive cells were rarely detected, ARG098 is believed
to induce apoptosis in tissues after injection because
ARG098 clearly induced apoptosis in vitro.
On the other hand, IgM can activate the comple-
ment system [33] and another part of the mechanism
by which ARG098 reduces synovial hyperplasia may
be explained through this system. Induction of apop-
tosis and activation of the complement system by
ARG098 may contribute to the inhibition of synovial
growth in vivo. Further experiments concerning apop-
tosis induction and complement system activation are
necessary to elucidate the pharmacological efficacy of
ARG098 in the treatment of synovial hyperplasia as
well as on events that occur in joints following
ARG098 injection.
(A) (B)
(C) (D)
Figure 6 Histopathological analyses of RA synovial grafts in the SCID-HuRAg model and the effects of ARG098. RA synovial tissue
samples were stained with hematoxylin and eosin (HE). (A) RA synovial tissue before implantation, (B) an untreated graft, (C) 10 μg human IgM-
injected graft, and (D) 10 μg anti-APO-1 IgM-injected graft.
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spread in naïve cartilage lead to cartilage destruction
[34]. This means that inhibition of the RA synovial cells
by ARG098 may not only directly protect the cartilage
in contact with the overgrown synovium but may also
protect the naïve cartilage and inhibit the spread of the
disease.
It may be expected that biological removal of the RA
synovium will become a new complementary therapy
with systemic anti-rheumatic drugs in future.
Conclusions
ARG098, a novel anti-Fas/APO-1/CD95 monoclonal
antibody, exhibits potency for treating RA synovial
hyperplasia, which plays crucial roles in joint destruction
in RA patients, by decreasing the numbers of RA syno-
viocytes and synovium-infiltrating lymphocytes via Fas-
mediated apoptosis. Taken together, these results sug-
gest that ARG098 might be a potential RA therapy that
directly suppresses synovial activity and decreases carti-
lage destruction when delivered by intra-articular injec-
tion. ARG098 P1/2 clinical studies in RA patients are
currently being performed in Japan and Europe. The
results of these studies are eagerly anticipated.
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